Background
==========

Uterine smooth muscle tumor is the most common clinically diagnosed tumor in women. It is generally divided into benign smooth muscle tumor, malignant leiomyosarcoma, and special type of smooth muscle tumor \[[@b1-medscimonit-26-e923749]\]. Cell-rich smooth muscle tumor of the uterus is a special type of uterine leiomyoma. The cellular smooth muscle tumors and uterine leiomyosarcomas are mainly differentiated by pathology, but sometimes it is difficult to differentiate them only by cell morphology. Stathmin-1 (STMN1), a microtubule depolymerization-related protein widely expressed in the cytoplasm, participates in the assembly of microtubules and spindles, and promotes the proliferation, differentiation, and invasion of tumor cells \[[@b2-medscimonit-26-e923749],[@b3-medscimonit-26-e923749]\]. MKI67 is a kind of nuclear protein which is expressed in proliferating cell nuclei and is closely related to cell proliferation \[[@b4-medscimonit-26-e923749]--[@b6-medscimonit-26-e923749]\]. STMN1 and MKI67 play an important role in mitotic spindle formation and cell mitosis, and their abnormal expression is closely related to the occurrence and development of multiple tumors. After a systematic search of the PubMed database, only 1 study related to the expression of STMN1 in uterine smooth muscle tumors was identified \[[@b7-medscimonit-26-e923749]\]. The biological function of STMN1 and MKI67 in uterine smooth muscle tumor in not clear yet. Therefore, we performed this study to investigate the relationship between the expression of STMN1 and MKI67 in uterine smooth muscle tumor and their role in the development of uterine leiomyosarcoma.

Material and Methods
====================

STMN1 and MKI67 expression analysis
-----------------------------------

The expression levels of STMN1 and MKI67 genes in various tissues and solid tumor tissues were compared by searching the TCGA database. The searching conditions were "uterine leiomyosarcoma", " STMN1 and MKI67", and the species was restricted to human. At the same time, we compared the difference between STMN1 and MKI67 genes in the cancer tissues and adjacent normal tissues of uterine leiomyosarcoma patients. The condition of differential expression was that STMN1 and mki67 mRNA was upregulated or downregulated by more than 2-fold (\|log2FC\| \>1) (P\<0.05).

STMN1 and MKI67 related protein--protein interaction (PPI) network
------------------------------------------------------------------

A protein--protein interaction (PPI) network relevant STMN1 and MKI67 proteins was constructed by using the STRING database. The "Organism" searching condition was limited to "human". The "Protein name" searching condition was limited to "STMN1 or MKI67". The active interaction sources were restricted to "Text mining", "Experiments", "Databases", "Co-expression", "Neighborhood", "Gene Fusion", and "Co-expression". The minimum required interaction score was more than 0.7 \[[@b8-medscimonit-26-e923749]\]

STMN1 and MKI67 co-expression analysis
--------------------------------------

In the TCGA database, according to the co-expression relationship with STMN1 and MKI67 genes, the genes related to STMN1 and MKI67 were clustered, and 2 genes with the most significant positive correlation and negative correlation were selected for analysis. The correlation was analyzed by Pearson correlation test of gene expression levels. For survival analysis, the patients were divided into high (≥STMN1 or MKI67 medical expression) or low (\<STMN1 or MKI67 medical expression) expression groups according to the median expression of STMN1 and MKI67 genes mRNA in uterine leiomyosarcoma. We assessed the hazard ratio (HR) of survival difference between STMN1 and MKI67 gene high and low expression groups. The log rank test was used to compare the overall survival (OS) and progression-free survival (DFS) of high and low expression groups.

Real-time PCR assay
-------------------

Total RNA was extracted from cancer tissue by TRIzol^®^ reagent. Total RNA was reverse transcribed into cDNAs. Real-time PCR assay for detection STMN1 and MKI67 relative expression was performed using the SYBR^®^ Premix Ex Taq™ II kit (Takara Bio, Inc., Otsu, Japan). The primers used were:

1.  MKI67, For: 5′-CCACACTGTGTCGTCGTTTG-3′;

2.  Rev: 5′-CCGTGCGCTTATCCATTCA-3′.

3.  STMN1, For: 5′-GTACTTCTGGACTCACGGGC-3′;

4.  Rev: 5′-AAGGCAAGAGTGGTCTGCTC-3′.

The relative expression levels of STMN1 and MKI67 mRNA were calculated using the formula 2^−ΔΔCt^.

STMN1 and MKI67 immunohistochemistry (IHC) assay
------------------------------------------------

Seventy-two patients who received hysterectomy were included from Wenzhou People's Hospital, the First Affiliated Hospital, and the Second Affiliated Hospital of Wenzhou Medical University from January 2013 to June 2016. Signed informed consent was obtained in all the included subjects and the work was approved by the Ethics Committee of Second Affiliated Hospital of Wenzhou Medical University. Myomectomy or hysterectomy were performed in patients with uterine smooth muscle tumors and cell-rich smooth muscle tumor and total hysterectomy plus double appendage resection was performed in patients with uterine leiomyosarcoma, with or without pelvic lymphadenectomy. Most of the patients had menstrual changes or abdominal mass, and there was no history of myomectomy. The 72 patients were divided into 4 groups according to the histopathological results: uterine normal smooth muscle tissue (UNSM=30), uterine leiomyoma (UL=30), uterine cellular leiomyoma (UCL=24), and uterine leiomyosarcoma (ULS=18).

The protein expression levels of STMN1 and MKI67 were detected by immunohistochemistry assay. For STMN1 expression, the staining intensity score of each field was multiplied by the percentage of positive cells \[[@b3-medscimonit-26-e923749]\], and the average value was obtained: no staining was scored as 0 points, light-yellow was scored as 1 point, brown-yellow was scored as 2 points, and brown was scored as 3 points. According to the percentage of positive cells, scores were: 5% or less = 0 point, 6--25%=1 point, 26--50%=2 points, 51--75%=3 points, and \>75%=4 points. 0 points was negative, 1--4 was weak positive, 5--8 was moderate positive, and 9--12 was strong positive. In the MKI67 group, only the percentage of positive cells was scored \[[@b6-medscimonit-26-e923749]\], and the average value was taken as the staining score \[[@b7-medscimonit-26-e923749]\]: \<15%=negative, 16--30%=weak positive, more than 30% =strong positive.

Statistical analysis
--------------------

SPSS17.0 software was applied for data analysis and measurement data are expressed as χ̄±s and were compared by ANOVA. Count data are expressed by relative number and were compared by chi-square test. Survival differences between the STMN1 and MKI67 gene high and low expression group were analyzed by log rank test, and P\<0.05 was regarded as indicating a statistically significant difference.

Results
=======

STMN1 and MKI67 mRNA expression
-------------------------------

In normal tissues, the expression of STMN1 gene mRNA was highest in the spinal cord, brain, and testis tissues, and the lowest in skeletal muscle, pancreas, and liver tissues ([Figure 1A](#f1-medscimonit-26-e923749){ref-type="fig"}). In tumor tissues, the expression levels were higher in testicular, cervical, and endometrial cancers ([Figure 1B](#f1-medscimonit-26-e923749){ref-type="fig"}). In uterine leiomyosarcoma, the expression level of STMN1 mRNA in cancer tissue was significantly higher than that of normal uterine smooth muscle tissue ([Figure 1C, 1D](#f1-medscimonit-26-e923749){ref-type="fig"}). However, the expression level of STMN1 gene mRNA was not related to the clinical stages of uterine sarcoma (P=0.214) ([Figure 1E](#f1-medscimonit-26-e923749){ref-type="fig"}). For the MKI67 gene, the mRNA expression in uterine leiomyosarcoma tissue was also significantly higher than that of normal uterine smooth muscle tissue ([Figure 2](#f2-medscimonit-26-e923749){ref-type="fig"}).

PPI network of STMN1 and MKI67
------------------------------

Through searching the STRING database, a protein--protein interaction (PPI) network of STMN1 and MKI67 was constructed. There were 20 proteins closely interacting with STMN1 and MKI67, and the protein--protein interaction network was significantly enriched (P\<0.05) ([Figure 3](#f3-medscimonit-26-e923749){ref-type="fig"}).

STMN1 and MKI67 co-expression analysis
--------------------------------------

Cluster analysis was carried out on positive and negative expression of the STMN1 gene ([Figure 4](#f4-medscimonit-26-e923749){ref-type="fig"}). The strongest positive correlation was found between STMN2 and STMN1 gene (r=0.710, P\<0.05) ([Figure 5A](#f5-medscimonit-26-e923749){ref-type="fig"}). The strongest negative correlation was found between SIRPB1 and STMN1 (r=−0.578, P\<0.05) ([Figure 5B](#f5-medscimonit-26-e923749){ref-type="fig"}) \[[@b9-medscimonit-26-e923749]\]. For the MKI67 gene, there was a positive correlative with KIF11 (r=0.771, P\<0.05) and negative correlation with RNF149 (r=−0.577, P\<0.05) ([Figures 6](#f6-medscimonit-26-e923749){ref-type="fig"}, [7](#f7-medscimonit-26-e923749){ref-type="fig"}).

Gene ontology (GO) enrichment
-----------------------------

STMN1 and MKI67 were mainly enriched in the mitotic cell cycle, mitotic cell cycle process, and cell cycle for biological process ([Table 1](#t1-medscimonit-26-e923749){ref-type="table"}); enriched in the microtubule cytoskeleton, spindle, and cytoskeletal part for cellular component ([Table 2](#t2-medscimonit-26-e923749){ref-type="table"}); and mainly enriched in the kinase binding, purine ribonucleotide binding, and histone kinase activity for molecular function ([Table 3](#t3-medscimonit-26-e923749){ref-type="table"}).

KEGG pathway enrichment
-----------------------

STMN1 and MKI67 genes were mainly enriched in the pathways of cell cycle, gap junction, and progesterone-mediated oocyte maturation ([Figure 8](#f8-medscimonit-26-e923749){ref-type="fig"}, [Table 4](#t4-medscimonit-26-e923749){ref-type="table"}).

Survival analysis
-----------------

According to the median expression of STMN1 and MKI67 gene mRNA in uterine leiomyosarcoma, the patients were divided into high and low expression groups. The prognosis analysis showed that the high and low expression of STMN1 and MKI67 gene mRNA was not related to overall or disease-free survival (P\>0.05) ([Figure 9](#f9-medscimonit-26-e923749){ref-type="fig"}).

STMN1 and MKI67 expression examined by real-time PCR and IHC assay
------------------------------------------------------------------

Real-time PCR results indicated that STMN1 and MKI67 mRNA levels were significantly different in the uterine normal smooth muscle tissue (UNSM), uterine leiomyoma (UL), uterine cellular leiomyoma (UCL), and uterine leiomyosarcoma (ULS) ([Figure 10](#f10-medscimonit-26-e923749){ref-type="fig"}). STMN1 protein was mainly positively expressed in the cytoplasm of tumor cells with light-yellow or brownish-brown granules. MKI67 protein positive reaction was mainly located in the nucleus of tumor cells with light-yellow or brownish-brown granules ([Figure 11](#f11-medscimonit-26-e923749){ref-type="fig"}). The positive rate of STMN1 protein in uterine leiomyosarcoma was 100.00%, which was significantly higher than that of the other 3 groups (χ^2^=11.72, P=0.008). However, there was no significant difference in positive expression of STMN1 protein among the UNSM, UL, and UCL groups (χ^2^ *UNSM, UL*=1.76, *P*=0.18; χ^2^ *UNSM, UCL*=0.98, *P*=0.30; χ^2^ *UL, UCL*=0.07, *P*=0.79) ([Table 5](#t5-medscimonit-26-e923749){ref-type="table"}). The positive rate of KIM67 protein in uterine leiomyosarcoma was 77.78%, which was significantly higher than that of the other 3 groups (χ^2^=48.89, *P*=0.000). However, there was no significant difference between UNSM and UL in KIM67-positive rate (χ^2^ *UNSM, UL*=1.02, P=0.31) ([Table 5](#t5-medscimonit-26-e923749){ref-type="table"}).

Correlation between STMN1, MKI67 expression, clinical features, and prognosis
-----------------------------------------------------------------------------

There was no significant correlation between STMN1 and MKI67 expression and patient age, tumor diameter, tumor numbers, and clinical stages in the 4 groups ([Table 6](#t6-medscimonit-26-e923749){ref-type="table"}). STMN1 was positively expressed in all the uterine leiomyosarcoma patients. The median OS of STMN1-positive patients was 28.5 months. For MKI67, the median OS was 28.5 and 30.2 months for patients with MKI67-positive and -negative expression, respectively, but the difference was not significantly different (HR=1.34, p=0.68) ([Figure 12](#f12-medscimonit-26-e923749){ref-type="fig"}).

Diagnostic efficacy of STMN1 and MKI67 as biomarkers
----------------------------------------------------

The diagnostic sensitivity and specificity were 77.78% and 90.74% for STMN1 and MKI67, respectively, with positive predictive value and negative predictive value of 73.68% and 92.45%, respectively ([Table 7](#t7-medscimonit-26-e923749){ref-type="table"}).

Discussion
==========

This study assessed the expression of STMN1 and MKI67 in uterine smooth muscle tumors and their relationship with patients' clinical characteristics. The expression of STMN1 and MKI67 in uterine smooth muscle tumors was evaluated by immunohistochemical assay. The results showed that STMN1 and MKI67 were expressed at low levels in the myometrium, leiomyoma, and cell-rich smooth muscle tumors, but they were highly expressed in leiomyosarcoma. Further analysis demonstrated the expression of STMN1 and MKI67 in uterine smooth muscle tumors was not correlated with patient age, tumor size, or leiomyosarcoma clinical stages. The STMN1-positive expression rate in the diagnosis of uterine leiomyosarcoma were 100% and 31.48%, respectively, which was consistent with results of a 2015 study by Allen et al. \[[@b7-medscimonit-26-e923749]\]. Although the pathological diagnosis of most cases is mainly based on the HE staining of specimens, there are special types of uterine smooth muscle tumors, such as uterine highly cellular smooth muscle tumors, and uterine malignant potential uncertain smooth muscle tumors, for which the immunohistochemical assay cannot improve the diagnosis. STMN1 expression in uterine leiomyosarcoma has high sensitivity but low specificity. Compared with Allen \[[@b7-medscimonit-26-e923749]\] and other studies that only detected STMN1 and smooth muscle tumor of the uterus, our study combined the detection of MKI67 and STMN1 to improve the specificity for early diagnosis of uterine leiomyosarcoma.

Uterine smooth muscle tumor is the most commonly diagnosed neoplasm in gynecology. It can be divided into 3 categories: benign uterine leiomyoma, uterine leiomyosarcoma, and borderline uterine leiomyoma. One of the most common borderline leiomyomas is uterine cell-rich smooth muscle tumor. Under the microscope, the smooth muscle tumor with rich cells in the uterus shows that the tumor cells are rich, closely arranged, and braided. The size and morphology of the cells are still the same. There is no or little heteromorphism. It is difficult to distinguish a high cell-rich smooth muscle tumor from leiomyosarcoma. Uterine leiomyosarcoma, although rare, has a high degree of malignancy, accounting for 2% to 4% of the malignant tumors of the uterus and 1% of the malignant tumors of the female reproductive system \[[@b10-medscimonit-26-e923749]\], most of which have an extremely poor prognosis \[[@b11-medscimonit-26-e923749]\]. Carcinogenesis is a complex process with many factors and steps, in which many genes and factors participate. Among them, abnormal cell cycle regulation and chromosome instability have been proved to be important topics in oncology. Microtubule depolymerization protein STMN1 is a cell regulatory factor that can change the dynamic balance of the microtubule system by phosphorylation. STMN1 can promote the proliferation, differentiation, and invasion of tumor cells, which are involved in tumor prognosis \[[@b12-medscimonit-26-e923749]--[@b14-medscimonit-26-e923749]\]. STMN1 is overexpressed in ovarian cancer \[[@b15-medscimonit-26-e923749],[@b16-medscimonit-26-e923749]\], endometrial cancer \[[@b17-medscimonit-26-e923749]--[@b19-medscimonit-26-e923749]\], and cervical cancer \[[@b20-medscimonit-26-e923749],[@b21-medscimonit-26-e923749]\] and its expression level is negatively correlated with the therapeutic effect and prognosis of Taxol chemotherapy drugs. MKI67 is a cell cycle regulatory protein that is a marker of proliferative cell nuclei and is an indicator of tumor proliferation rate. With increased MKI67 expression level, the proliferation activity of tumor cells is also increased. Excessive cell division and proliferation have been proved to be an important part of malignant transformation. MKI67 is highly expressed in ovarian cancer \[[@b22-medscimonit-26-e923749]\], endometrial cancer \[[@b23-medscimonit-26-e923749]--[@b25-medscimonit-26-e923749]\], and cervical cancer \[[@b26-medscimonit-26-e923749]--[@b28-medscimonit-26-e923749]\], and is positively correlated with aggressive pathological factors such as advanced clinical stages, histological type, tumor differentiation, and myometrial invasion, and negatively correlated with prognosis. However, in the present study, we did not find a correlation between high expression of STMN1 and MKI67 and overall survival or disease-free survival in patients with uterine leiomyosarcoma. These negative results may due to the small sample size and limited statistical power. Our work has certain limitations. In the bioinformatics analysis part, the original data did not provide any information about serum STMN1 and MKI67 genes expression. All of the data about STMN1 and MKI67 genes expression were examined in the tumor and corresponding tissue. Therefore, we were unable to investigate the serum STMN1 and MKI67 genes expression level, and the clinical ability to predict the risk of sarcoma prior to surgery was limited. Another limitation is that gene expression testing needed to be performed in pretreatment biopsy specimens. However, biopsy is not recommended before surgery due to possible seeding of uterine leiomyosarcoma, which is highly malignant. Therefore, detection of expression of these genes difficult in clinical practice.

Conclusions
===========

The results of this study indicated that TMN1 and MKI67 are upregulated in uterine leiomyosarcoma and play important roles in its development. The combined detection of STMN1 and MKI67 has clinical importance in the early diagnosis of uterine leiomyosarcoma.
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![Expression of STMN1 gene in normal and different tumor tissues (**A:** Expression of STMN1 gene in normal tissues; **B:** Expression of STMN1 gene mRNA in various tumor tissues; **C:** Expression comparison of STMN1 gene mRNA in uterine leiomyosarcoma and corresponding normal tissues; **D:** STMN1 gene mRNA expression in cancer tissue was significantly higher than in the corresponding normal tissue of uterine leiomyosarcoma; **E:** STMN1 gene mRNA expression in different clinical stages of uterine leiomyosarcoma).](medscimonit-26-e923749-g001){#f1-medscimonit-26-e923749}

![Expression of MKI67 gene in normal and different tumor tissues (**A:** Expression of MKI67 gene in normal tissues; **B:** Expression of MKI67 gene mRNA in various tumor tissues; **C:** Expression comparison of MKI67 gene mRNA in leiomyosarcoma of uterus and corresponding normal tissues; **D:** MKI67 gene mRNA expression in cancer tissue was significantly higher than in the corresponding normal tissue of uterine leiomyosarcoma; **E:** MKI67 gene mRNA expression in different clinical stages of uterine leiomyosarcoma).](medscimonit-26-e923749-g002){#f2-medscimonit-26-e923749}

![Protein--protein interaction network (PPI) of STMN1 and MKI67(**A:** Both STMN1 and MKI67 interaction proteins included in the PPI; **B:** Only MKI67 interaction proteins included in the PPI; **C:** Only STMN1 interaction proteins included in the PPI)](medscimonit-26-e923749-g003){#f3-medscimonit-26-e923749}

![STMN1 gene co-expression analysis (**A:** Positive correlation gene co-expression heat-map; **B:** Negative correlation gene co-expression heat-map).](medscimonit-26-e923749-g004){#f4-medscimonit-26-e923749}

![STMN1 gene co-expression scatter plot (**A:** Positive correlation gene co-expression; **B:** Negative correlation gene co-expression).](medscimonit-26-e923749-g005){#f5-medscimonit-26-e923749}

![MKI67 gene co-expression analysis (**A:** Positive correlation gene co-expression heat-map; **B:** Negative correlation gene co-expression heat-map).](medscimonit-26-e923749-g006){#f6-medscimonit-26-e923749}

![MKI67 gene co-expression scatter plot (**A:** Positive correlation gene co-expression; **B:** Negative correlation gene co-expression).](medscimonit-26-e923749-g007){#f7-medscimonit-26-e923749}

![Bubble plot of KEGG pathway enrichment for STMN1 and MKI67.](medscimonit-26-e923749-g008){#f8-medscimonit-26-e923749}

![Survival curve of STMN1 and MKI67 expression and patient prognosis (**A:** Overall survival between STMN1 high and low expression group; **B:** Disease-free survival between STMN1 high and low expression group; **C:** Overall survival between MKI67 high and low expression group; **D:** Disease-free survival between MKI67 high and low expression group).](medscimonit-26-e923749-g009){#f9-medscimonit-26-e923749}

![Scatter plot of STMN1 and MIKI67 mRNA relative expression (**A:** STMN1 mRNA relative expression; **B:** MKI67 mRNA relative expression). \*\* p\<0.001](medscimonit-26-e923749-g010){#f10-medscimonit-26-e923749}

![STMN1 and MKI67 expression examined by IHC assay.](medscimonit-26-e923749-g011){#f11-medscimonit-26-e923749}

![The overall survival of uterine leiomyosarcoma patients with STMN1 and MKI67 expression (**A:** Survival curve of STMN1-positive uterine leiomyosarcoma patients; **B:** Survival curve comparison of MKI67-positive and -negative uterine leiomyosarcoma patients).](medscimonit-26-e923749-g012){#f12-medscimonit-26-e923749}

###### 

GO enrichment of STMN1 and MKI67 in biological process.

  Description                        Gene count   Background gene count   False discovery rate   Gene ratio
  ---------------------------------- ------------ ----------------------- ---------------------- ------------
  Mitotic cell cycle                 19           628                     7.68E-23               0.030255
  Mitotic cell cycle process         18           564                     8.07E-22               0.031915
  Cell cycle                         20           1263                    1.22E-19               0.015835
  Cell division                      15           483                     2.76E-17               0.031056
  Regulation of cell cycle process   15           684                     3.20E-15               0.02193
  Regulation of cell cycle           17           1129                    3.20E-15               0.015058
  Microtubule-based process          13           605                     1.27E-12               0.021488
  Regulation of mitotic cell cycle   13           608                     1.27E-12               0.021382
  Chromosome segregation             10           253                     8.82E-12               0.039526
  Regulation of nuclear division     9            184                     2.88E-11               0.048913

###### 

GO enrichment of STMN1 and MKI67 in cellular component.

  Description                                    Gene count   Background gene count   False discovery rate   Gene ratio
  ---------------------------------------------- ------------ ----------------------- ---------------------- ------------
  Microtubule cytoskeleton                       15           1118                    4.04E-12               0.013417
  Spindle                                        10           322                     6.46E-11               0.031056
  Cytoskeletal part                              15           1547                    1.46E-10               0.009696
  Microtubule                                    10           385                     1.81E-10               0.025974
  Intracellular non-membrane-bounded organelle   19           4005                    1.90E-09               0.004744
  Condensed chromosome                           7            215                     5.02E-08               0.032558
  Spindle pole                                   6            150                     1.82E-07               0.04
  Centrosome                                     8            468                     2.72E-07               0.017094
  Condensed chromosome, centromeric region       5            117                     1.95E-06               0.042735
  Spindle microtubule                            4            47                      2.52E-06               0.085106

###### 

GO enrichment of STMN1 and MKI67 in molecular function.

  Description                                  Gene count   Background gene count   False discovery rate   Gene ratio
  -------------------------------------------- ------------ ----------------------- ---------------------- ------------
  Kinase binding                               7            678                     0.00014                0.010324
  Purine ribonucleotide binding                11           1853                    0.00014                0.005936
  Histone kinase activity                      3            16                      0.00014                0.1875
  Purine ribonucleoside triphosphate binding   11           1794                    0.00014                0.006132
  Nucleoside-triphosphatase activity           7            778                     0.00021                0.008997
  Tubulin binding                              5            344                     0.00031                0.014535
  Protein kinase binding                       6            599                     0.00034                0.010017
  Protein C-terminus binding                   4            194                     0.00046                0.020619
  ATP binding                                  8            1462                    0.00083                0.005472
  Microtubule binding                          4            253                     0.001                  0.01581

###### 

KEGG pathway enrichment for STMN1 and MKI67.

  Description                               Count   Q value    Gene ratio
  ----------------------------------------- ------- ---------- ------------
  Cell cycle                                5       7.16E-06   0.04065
  Gap junction                              4       4.04E-05   0.045977
  Progesterone-mediated oocyte maturation   4       4.04E-05   0.042553
  Oocyte meiosis                            4       6.07E-05   0.034483
  Cellular senescence                       4       0.00015    0.025641
  Pathogenic *Escherichia coli* infection   3       0.00015    0.056604
  p53 signaling pathway                     3       0.00026    0.044118
  Apoptosis                                 3       0.0016     0.022222
  Phagosome                                 3       0.0018     0.02069
  Tight junction                            3       0.0024     0.017964
  Viral carcinogenesis                      3       0.0028     0.016393
  Epstein-Barr virus infection              2       0.0454     0.010309

###### 

STMN1 and MKI67 expression rate in NSMU, LU, CLU and LSU groups.

  Group   n    STMN1   MKI67        
  ------- ---- ------- ------- ---- ----
  NSMU    30   14      16      30   0
  LU      30   9       21      29   1
  CLU     24   8       16      18   6
  LSU     18   0       18      4    14

NSMU -- normal smooth muscular tissue of uterus; LU -- leiomyoma of uterus; CLU -- cellular leiomyoma of uterus; LSU -- leiomyosarcoma of uterus.

###### 

Correlation between STMN1, MKI67 expression and clinical features.

  Group            Features   STMN1    MKI67             
  ---------------- ---------- -------- -------- -------- -------
  NSMU             Age        0.163    0.389    0.012    0.951
  LU               Age        0.075    0.693    −0.113   0.553
  Tumor diameter   −0.210     0.265    0.299    0.109    
  Tumor number     0.238      0.205    −0.288   0.122    
  CLU              Age        −0.194   0.363    −0.357   0.087
  Tumor diameter   −0.040     0.854    −0.160   0.456    
  Tumor number     0.252      0.235    0.165    0.442    
  LSU              Age        0.414    0.088    0.285    0.252
  Clinical stage   0.414      0.088    0.316    0.202    

NSMU -- normal smooth muscular tissue of uterus; LU -- leiomyoma of uterus; CLU -- cellular leiomyoma of uterus; LSU -- leiomyosarcoma of uterus.

###### 

Diagnostic efficacy of STMN1, MKI67 as biomarker for STMN1, MKI67.

  Gene                                                              Expression   Benign   Malignant   SEN (%)   SPE (%)   PPV (%)   NPV (%)
  ----------------------------------------------------------------- ------------ -------- ----------- --------- --------- --------- ---------
  STMN1                                                                                               100.00    31.48     32.73     100.00
                                                                    Positive     37       18                                        
  Negative                                                          17           0                                                  
  MKI67                                                                                               77.78     87.04     66.67     92.16
                                                                    Positive     7        14                                        
  Negative                                                          47           4                                                  
  STMN1+ MKI67                                                                                        77.78     90.74     73.68     92.45
                                                                    Positive     5        14                                        
  Negative[\*](#tfn3-medscimonit-26-e923749){ref-type="table-fn"}   49           4                                                  

Either STMN1 negative or MKI67 negative.

SEN -- sensitivity; SEP -- specificity; PPV -- positive predictive value; NPV -- negative predictive value.
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